The MOLE Clinic, the only UK private clinic group dedicated to skin cancer screening, has announced the appointment of a new Chief Executive Officer, Annie Meharg.

With more than 21 years of trusted expertise in the early detection of skin cancer and mole removal, The MOLE Clinic continues to set the standard for private skin cancer screening. 

The appointment of Annie Meharg marks the next step in strengthening its mission to deliver outstanding patient care, while expanding access to early detection services nationwide.

Annie joins the business with distinguished experience in healthcare innovation. Before joining The MOLE Clinic, she served as Chief Commercial Officer at leading telediagnostics platform 4ways, where she played a key role in advancing technology-enabled healthcare services. 

Her career has been defined by a passion for enhancing patient experiences through the integration of cutting-edge solutions within the healthcare sector.

Since August 2024, The MOLE Clinic has expanded its footprint from four to nine sites, with a strategic growth plan set to drive continued expansion over the next few years. From its inception, the company has been at the forefront of innovation in skin cancer diagnosis, pioneering the use of artificial intelligence to enhance screening accuracy and seamlessly integrating advanced technology with the clinical expertise of its specialist nurses and doctors.

Speaking of her appointment, Annie Meharg, Chief Executive Officer at The MOLE Clinic said: “I’m delighted to be joining the passionate team at The MOLE Clinic. Together, I look forward to driving the next chapter of growth and broadening access to our services, while strengthening our mission to deliver outstanding care and advance the early detection of skin cancer.”

Christopher Langley, Chairman at The MOLE Clinic, added: “We are thrilled to welcome Annie to The MOLE Clinic. Her extensive experience in the healthcare sector makes her an invaluable addition to our leadership team. 

With Annie’s vision and energy, we are confident the clinic will continue to expand its impact throughout the country.”

Alistair Armstrong, Impact Fund Partner at Palatine, commented: “Annie has a strong track record of guiding pioneering healthcare organisations such as The MOLE Clinic through ambitious growth journeys, while upholding the highest standards of customer service and governance. 

We are delighted to have Annie on board as we embark on our own exciting phase of growth in the years ahead.”

For more than 21 years, The MOLE Clinic has been helping patients with early skin cancer detection and mole removal. Each year, over 35,000 people visit its clinics across the UK, including locations in London (Harley Street, Oxford Circus, Moorgate, and London Bridge), as well as Manchester, Bristol, Edinburgh, and Glasgow.

The brand’s mission is to help lower the UK skin cancer mortality rate by detecting skin cancer early. This is achieved by developing innovative, highest quality screening services and making those services widely available and easily accessible to the UK public and NHS GPs.

The MOLE Clinic is Bupa recognised, approved by Alliance Surgical & Vitality Health, approved NHS Suppliers, and Care Quality Commission Regulated.